Evofem Biosciences, Inc. (EVFM)
USD 0.01
(-1.11%)
USD 0.01
(-1.11%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 11.7 Million USD | -20.1% |
| 2022 | 12.42 Million USD | 196.54% |
| 2021 | 4.18 Million USD | 19140.91% |
| 2020 | -22 Thousand USD | 97.57% |
| 2019 | -905 Thousand USD | -245.42% |
| 2018 | -262 Thousand USD | -7.38% |
| 2017 | -244 Thousand USD | -253.14% |
| 2016 | -69.09 Thousand USD | -18.26% |
| 2015 | -58.42 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | -100.0% |
| 2012 | 100 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.86 Million USD | -25.09% |
| 2024 Q2 | 3.34 Million USD | 18.57% |
| 2023 Q2 | 165 Thousand USD | -96.28% |
| 2023 Q1 | 4.43 Million USD | 2283.74% |
| 2023 FY | 9.92 Million USD | -20.1% |
| 2023 Q4 | 3.81 Million USD | 18.46% |
| 2023 Q3 | 3.22 Million USD | 1853.33% |
| 2022 Q1 | 3.18 Million USD | 75.48% |
| 2022 FY | 12.42 Million USD | 196.54% |
| 2022 Q4 | -203 Thousand USD | -104.33% |
| 2022 Q3 | 4.69 Million USD | -1.22% |
| 2022 Q2 | 4.74 Million USD | 49.11% |
| 2021 Q2 | 1.01 Million USD | 69.95% |
| 2021 Q3 | 757 Thousand USD | -25.64% |
| 2021 FY | 4.18 Million USD | 19140.91% |
| 2021 Q4 | 1.81 Million USD | 139.76% |
| 2021 Q1 | 599 Thousand USD | 3423.53% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q4 | 17 Thousand USD | 143.59% |
| 2020 Q3 | -39 Thousand USD | 0.0% |
| 2020 FY | -22 Thousand USD | 97.57% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 FY | -905 Thousand USD | -245.42% |
| 2018 FY | -262 Thousand USD | -7.38% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | -244 Thousand USD | -253.14% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | -69.09 Thousand USD | -18.26% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | -58.42 Thousand USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 FY | - USD | -100.0% |
| 2013 Q4 | - USD | 0.0% |
| 2012 FY | 100 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 480050.8% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 3763.769% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 90.172% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 145.376% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 24356.615% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 9521.252% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 21.955% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -377269.439% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -19.522% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -17709.761% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 34378.184% |
| Mesoblast Limited | -35.16 Million USD | 133.286% |
| Marizyme, Inc. | 457.7 Thousand USD | -2457.559% |
| Genus plc | 178.7 Million USD | 93.449% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 94.682% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -18712.072% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -2753.973% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 106518.182% |
| ContraFect Corporation | -154 Thousand USD | 7701.299% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 23512.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -15149.932% |
| IMV Inc. | -962.29 Thousand USD | 1316.463% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 3120.895% |
| MultiCell Technologies, Inc. | 49.32 USD | -23734693.187% |
| ONE Bio Corp. | 20.12 Million USD | 41.835% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 70.928% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -23838.65% |
| Q BioMed Inc. | -8988.00 USD | 130340.32% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 58.57% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 75994.71% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 73.61% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 1125.428% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -16622.857% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 236489.338% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -8231.673% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 12104.307% |
| GB Sciences, Inc. | -624.00 USD | 1876061.538% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 13707.198% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.845% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 5627984.615% |
| Enzolytics Inc. | 30.7 Thousand USD | -38020.36% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -2326.451% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 98.944% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 2375.174% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -1796.065% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 97.142% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 132281.572% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 14060.811% |
| Kadimastem Ltd | -630.13 Thousand USD | 1957.688% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -1084.841% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -21.798% |
| BioStem Technologies, Inc. | 15.42 Million USD | 24.109% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 99010.013% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -6530.041% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -6530.041% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -762.547% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 40465.517% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -2501.085% |
| SYBLEU INC | 11.69 Thousand USD | -99985.499% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -154.036% |
| Bioxytran, Inc. | -8285.00 USD | 141391.491% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 3238.338% |
| Neutra Corp. | 14.33 Thousand USD | -81560.272% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 14375.61% |
| PureTech Health plc | -1.6 Million USD | 830.256% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 1269.155% |
| IXICO plc | 3.27 Million USD | -257.982% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 1786.744% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 753.601% |
| CSL Limited | 7.7 Billion USD | 99.848% |
| Cellectis S.A. | 18 Thousand USD | -64933.333% |